12:38 PM EST, 12/19/2024 (MT Newswires) -- Marker Therapeutics ( MRKR ) said Thursday it has agreed to sell securities worth $16.1 million to investors including Blue Owl Healthcare Opportunities (OWL), New Enterprise Associates and Aisling Capital in a private placement.

Marker said it will sell about 5 million shares, or pre-funded warrants, and warrants to buy up to around 5 million shares at a price of $3.20 per share and accompanying warrant.

Net proceeds will be allocated toward supporting the phase 1 Apollo trial studying the company's multi-antigen recognizing T cell product, it added.

The company's shares were down 4.2% in recent trading.

Price: 3.81, Change: -0.22, Percent Change: -5.46